BCL2 and cancer: In conclusion, the novel technology employed in BH3-profiling, in conjunction with determination of the baseline expression levels of BCL-2 family members, provides useful insights into the mode of action of novel anti-cancer agents in inducing apoptosis and should be tested prospectively in Phase 1 clinical trials of novel agents targeting apoptosis pathways.